Centre Hospitalier Lyon Sud ( Site 4606)

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)	Neoplasms by Histologic Type, autosomal dominant Parkinson disease 4, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-02-18		NCT06483334

Clinical trials